Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.

Chlenski A, Park C, Dobratic M, Salwen HR, Budke B, Park JH, Miller R, Applebaum MA, Wilkinson E, Nakamura Y, Connell PP, Cohn SL.

Mol Cancer Ther. 2019 Jan 23. pii: molcanther.0819.2018. doi: 10.1158/1535-7163.MCT-18-0819. [Epub ahead of print]

PMID:
30674566
2.

DNA Methylation Controls Metastasis-Suppressive 14q32-Encoded miRNAs.

Oshima G, Poli EC, Bolt MJ, Chlenski A, Forde M, Jutzy JMS, Biyani N, Posner MC, Pitroda SP, Weichselbaum RR, Khodarev NN.

Cancer Res. 2019 Feb 1;79(3):650-662. doi: 10.1158/0008-5472.CAN-18-0692. Epub 2018 Dec 11.

PMID:
30538122
3.

Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids.

Chlenski A, Dobratic M, Salwen HR, Applebaum M, Guerrero LJ, Miller R, DeWane G, Solomaha E, Marks JD, Cohn SL.

Oncotarget. 2016 Nov 22;7(47):77696-77706. doi: 10.18632/oncotarget.12773.

4.

Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients.

Applebaum MA, Jha AR, Kao C, Hernandez KM, DeWane G, Salwen HR, Chlenski A, Dobratic M, Mariani CJ, Godley LA, Prabhakar N, White K, Stranger BE, Cohn SL.

Oncotarget. 2016 Nov 22;7(47):76816-76826. doi: 10.18632/oncotarget.12713.

5.

Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.

Pinto N, Mayfield JR, Raca G, Applebaum MA, Chlenski A, Sukhanova M, Bagatell R, Irwin MS, Little A, Rawwas J, Gosiengfiao Y, Delattre O, Janoueix-Lerosey I, Lapouble E, Schleiermacher G, Cohn SL.

Pediatr Blood Cancer. 2016 Jun;63(6):1019-23. doi: 10.1002/pbc.25934. Epub 2016 Feb 10.

6.

Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounterâ„¢ system.

Stricker TP, Morales La Madrid A, Chlenski A, Guerrero L, Salwen HR, Gosiengfiao Y, Perlman EJ, Furman W, Bahrami A, Shohet JM, Zage PE, Hicks MJ, Shimada H, Suganuma R, Park JR, So S, London WB, Pytel P, Maclean KH, Cohn SL.

Mol Oncol. 2014 May;8(3):669-78. doi: 10.1016/j.molonc.2014.01.010. Epub 2014 Jan 31.

7.

Histone-lysine methyltransferase EHMT2 is involved in proliferation, apoptosis, cell invasion, and DNA methylation of human neuroblastoma cells.

Lu Z, Tian Y, Salwen HR, Chlenski A, Godley LA, Raj JU, Yang Q.

Anticancer Drugs. 2013 Jun;24(5):484-93. doi: 10.1097/CAD.0b013e32835ffdbb.

8.

Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma.

Gu S, Tian Y, Chlenski A, Salwen HR, Lu Z, Raj JU, Yang Q.

Anticancer Drugs. 2012 Nov;23(10):1054-66.

9.

Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma.

Ostler KR, Yang Q, Looney TJ, Zhang L, Vasanthakumar A, Tian Y, Kocherginsky M, Raimondi SL, DeMaio JG, Salwen HR, Gu S, Chlenski A, Naranjo A, Gill A, Peddinti R, Lahn BT, Cohn SL, Godley LA.

Cancer Res. 2012 Sep 15;72(18):4714-23. doi: 10.1158/0008-5472.CAN-12-0886. Epub 2012 Jul 18.

10.

Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.

Kakodkar NC, Peddinti RR, Tian Y, Guerrero LJ, Chlenski A, Yang Q, Salwen HR, Maitland ML, Cohn SL.

Pediatr Blood Cancer. 2012 Oct;59(4):642-7. doi: 10.1002/pbc.24004. Epub 2011 Dec 6.

PMID:
22147414
11.

Secreted protein acidic and rich in cysteine is a matrix scavenger chaperone.

Chlenski A, Guerrero LJ, Salwen HR, Yang Q, Tian Y, Morales La Madrid A, Mirzoeva S, Bouyer PG, Xu D, Walker M, Cohn SL.

PLoS One. 2011;6(9):e23880. doi: 10.1371/journal.pone.0023880. Epub 2011 Sep 16.

12.

The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth.

Kakodkar NC, Peddinti R, Kletzel M, Tian Y, Guerrero LJ, Undevia SD, Geary D, Chlenski A, Yang Q, Salwen HR, Cohn SL.

Pediatr Blood Cancer. 2011 Jan;56(1):164-7. doi: 10.1002/pbc.22639.

13.

Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines.

Yang Q, Tian Y, Ostler KR, Chlenski A, Guerrero LJ, Salwen HR, Godley LA, Cohn SL.

BMC Cancer. 2010 Jun 14;10:286. doi: 10.1186/1471-2407-10-286.

14.

Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors.

Chlenski A, Guerrero LJ, Peddinti R, Spitz JA, Leonhardt PT, Yang Q, Tian Y, Salwen HR, Cohn SL.

Mol Cancer. 2010 Jun 4;9:138. doi: 10.1186/1476-4598-9-138.

15.

Modulation of matrix remodeling by SPARC in neoplastic progression.

Chlenski A, Cohn SL.

Semin Cell Dev Biol. 2010 Feb;21(1):55-65. doi: 10.1016/j.semcdb.2009.11.018. Epub 2009 Dec 1. Review.

PMID:
19958839
16.

A novel interplay between Epac/Rap1 and mitogen-activated protein kinase kinase 5/extracellular signal-regulated kinase 5 (MEK5/ERK5) regulates thrombospondin to control angiogenesis.

Doebele RC, Schulze-Hoepfner FT, Hong J, Chlenski A, Zeitlin BD, Goel K, Gomes S, Liu Y, Abe MK, Nor JE, Lingen MW, Rosner MR.

Blood. 2009 Nov 12;114(20):4592-600. doi: 10.1182/blood-2009-04-217042. Epub 2009 Aug 26.

17.

Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors.

Zeine R, Salwen HR, Peddinti R, Tian Y, Guerrero L, Yang Q, Chlenski A, Cohn SL.

Mod Pathol. 2009 Jul;22(7):950-8. doi: 10.1038/modpathol.2009.52. Epub 2009 May 1.

18.

Prominent microvascular proliferation in clinically aggressive neuroblastoma.

Peddinti R, Zeine R, Luca D, Seshadri R, Chlenski A, Cole K, Pawel B, Salwen HR, Maris JM, Cohn SL.

Clin Cancer Res. 2007 Jun 15;13(12):3499-506.

19.

Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with poor outcome.

Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, Brumback BA, London WB, Cohn SL.

Clin Cancer Res. 2007 Jun 1;13(11):3191-7.

20.

Thrombospondin-1 peptide ABT-510 combined with valproic acid is an effective antiangiogenesis strategy in neuroblastoma.

Yang Q, Tian Y, Liu S, Zeine R, Chlenski A, Salwen HR, Henkin J, Cohn SL.

Cancer Res. 2007 Feb 15;67(4):1716-24.

21.

SPARC enhances tumor stroma formation and prevents fibroblast activation.

Chlenski A, Guerrero LJ, Yang Q, Tian Y, Peddinti R, Salwen HR, Cohn SL.

Oncogene. 2007 Jul 5;26(31):4513-22. Epub 2007 Jan 29.

PMID:
17260013
22.

SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix.

Chlenski A, Liu S, Guerrero LJ, Yang Q, Tian Y, Salwen HR, Zage P, Cohn SL.

Int J Cancer. 2006 Jan 15;118(2):310-6.

23.

'Cross-talk' between Schwannian stroma and neuroblasts promotes neuroblastoma tumor differentiation and inhibits angiogenesis.

Liu S, Tian Y, Chlenski A, Yang Q, Salwen HR, Cohn SL.

Cancer Lett. 2005 Oct 18;228(1-2):125-31. Review.

PMID:
15935552
24.

Cross-talk between Schwann cells and neuroblasts influences the biology of neuroblastoma xenografts.

Liu S, Tian Y, Chlenski A, Yang Q, Zage P, Salwen HR, Crawford SE, Cohn SL.

Am J Pathol. 2005 Mar;166(3):891-900.

25.

Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.

Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL.

Clin Cancer Res. 2004 Dec 15;10(24):8493-500.

26.
27.

Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma.

Yang Q, Liu S, Tian Y, Hasan C, Kersey D, Salwen HR, Chlenski A, Perlman EJ, Cohn SL.

Cancer Res. 2004 Jul 1;64(13):4531-8.

28.

Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma.

Yang QW, Liu S, Tian Y, Salwen HR, Chlenski A, Weinstein J, Cohn SL.

Cancer Res. 2003 Oct 1;63(19):6299-310.

29.

The regulation of angiogenesis in neuroblastoma.

Chlenski A, Liu S, Cohn SL.

Cancer Lett. 2003 Jul 18;197(1-2):47-52. Review.

PMID:
12880959
30.

SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis.

Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, Yang Q, Salwen HR, Farrer R, Bray J, Cohn SL.

Cancer Res. 2002 Dec 15;62(24):7357-63.

31.

Role of peroxisome proliferator-activated receptor gamma and its ligands in non-neoplastic and neoplastic human urothelial cells.

Nakashiro KI, Hayashi Y, Kita A, Tamatani T, Chlenski A, Usuda N, Hattori K, Reddy JK, Oyasu R.

Am J Pathol. 2001 Aug;159(2):591-7.

32.

Androgen receptor expression in androgen-independent prostate cancer cell lines.

Chlenski A, Nakashiro K, Ketels KV, Korovaitseva GI, Oyasu R.

Prostate. 2001 Apr;47(1):66-75.

PMID:
11304731
33.

Organization and expression of the human zo-2 gene (tjp-2) in normal and neoplastic tissues.

Chlenski A, Ketels KV, Korovaitseva GI, Talamonti MS, Oyasu R, Scarpelli DG.

Biochim Biophys Acta. 2000 Oct 2;1493(3):319-24.

PMID:
11018256
34.

Analysis of the kinase-related protein gene found at human chromosome 3q21 in a multi-gene cluster: organization, expression, alternative splicing, and polymorphic marker.

Watterson DM, Schavocky JP, Guo L, Weiss C, Chlenski A, Shirinsky VP, Van Eldik LJ, Haiech J.

J Cell Biochem. 1999 Dec 1;75(3):481-91.

PMID:
10536370
35.

zo-2 gene alternative promoters in normal and neoplastic human pancreatic duct cells.

Chlenski A, Ketels KV, Engeriser JL, Talamonti MS, Tsao MS, Koutnikova H, Oyasu R, Scarpelli DG.

Int J Cancer. 1999 Oct 29;83(3):349-58.

36.

Tight junction protein ZO-2 is differentially expressed in normal pancreatic ducts compared to human pancreatic adenocarcinoma.

Chlenski A, Ketels KV, Tsao MS, Talamonti MS, Anderson MR, Oyasu R, Scarpelli DG.

Int J Cancer. 1999 Jul 2;82(1):137-44.

Supplemental Content

Loading ...
Support Center